{"id":229,"date":"2025-12-05T15:22:37","date_gmt":"2025-12-05T15:22:37","guid":{"rendered":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/?p=229"},"modified":"2025-12-05T15:23:02","modified_gmt":"2025-12-05T15:23:02","slug":"writing-assignment-4","status":"publish","type":"post","link":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/2025\/12\/05\/writing-assignment-4\/","title":{"rendered":"Writing Assignment #4"},"content":{"rendered":"\n<p class=\"has-text-align-center\">A Breakthrough in Huntington\u2019s Disease<\/p>\n\n\n\n<p><br>       Gene therapy trials in the UK led by professors Sarah Tabrizi and Ed Wild have given<br>hope to the thousands of people with Huntington\u2019s disease. Until now, this devastating disease<br>has been incurable. It is an autosomal dominant disease; a child with an affected parent has a<br>50% chance of inheritance. Beginning in the coding region of the huntingtin gene, an expansion<br>of the cytosine-adenine-guanine (CAG) trinucleotide sequence occurs. An individual with thirty-<br>six repeats or more is highly likely to develop the disease, with full expression typically starting<br>at 40 repeats. With an increased number of CAG repeats, the huntingtin protein makes toxic<br>versions of said gene, steadily damaging nerve cells. This damage can then lead to involuntary<br>movement, cognitive decline, psychiatric symptoms, speech difficulties, and even death. While<br>currently incurable, the results of Tabrizi and Wild\u2019s trials have shown to slow down the<br>progression of Huntington\u2019s disease in patients by 75% after three years. A drug with the ability<br>to inactivate the mutant proteins was surgically injected into twenty-nine patients in the UK and<br>US through a complex 12\u201320-hour procedure. Scientists utilize a harmless virus to modify it so<br>that it delivers a specific sequence of DNA into brain cells. The procedure requires surgically<br>entering two separate regions of the brain through a microcatheter. Once delivered, it instructs<br>the cells to produce this genetic material that disables the instructions for mutant huntingtin<br>protein. Throughout the trial, patients undergo testing concerning their motor skills, cognitive<br>abilities, and the quality of their daily lives. Then, after three years, the results demonstrated a<br>decrease in progression of an average of 75%, saving more brain cells. With this treatment, those<br>affected by Huntington\u2019s disease can delay its impact on their health and lead a longer, healthier<br>lifestyle. Although remarkable, the complexity of the procedure will make the drug unavailable<br>and expensive for some, and it still must receive approval.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-text-align-center\">APA Citation<\/p>\n\n\n\n<p class=\"has-text-align-left\">Devlin, H. (2025, September 24). Huntington\u2019s disease treated successfully for first time in UK                                        gene therapy trial. The Guardian.                              https:\/\/www.theguardian.com\/science\/2025\/sep\/24\/huntingtons-disease-treated-                                 successfully-for-first-time-in-gene-therapy-trial<\/p>\n\n\n\n<p class=\"has-text-align-center\"><br>References<\/p>\n\n\n\n<p class=\"has-text-align-left\"><br>1.Jurcau, A. Molecular pathophysiological mechanisms in Huntington\u2019s disease. Biomedicines                        10, 1432 (2022).<br>2.Kim, A. et al. New Avenues for the treatment of Huntington\u2019s disease. International Journal of  Molecular Sciences 22, 8363 (2021).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Breakthrough in Huntington\u2019s Disease Gene therapy trials in the UK led by professors Sarah Tabrizi and Ed Wild have givenhope to the thousands of people with Huntington\u2019s disease. Until now, this devastating diseasehas been incurable. It is an autosomal&#8230; <a class=\"more-link\" href=\"https:\/\/sites.wp.odu.edu\/genetics-dulce\/2025\/12\/05\/writing-assignment-4\/\">Continue Reading &rarr;<\/a><\/p>\n","protected":false},"author":31223,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","wds_primary_category":1},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/posts\/229"}],"collection":[{"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/users\/31223"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/comments?post=229"}],"version-history":[{"count":2,"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/posts\/229\/revisions"}],"predecessor-version":[{"id":232,"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/posts\/229\/revisions\/232"}],"wp:attachment":[{"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/media?parent=229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/categories?post=229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sites.wp.odu.edu\/genetics-dulce\/wp-json\/wp\/v2\/tags?post=229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}